• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Arcellx Inc.

    5/15/25 4:30:15 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ACLX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    Arcellx, Inc.

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)


    03940C100

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    03940C100


    1Names of Reporting Persons

    Perceptive Advisors LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,926,478.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,926,478.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,926,478.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.3 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    03940C100


    1Names of Reporting Persons

    Joseph Edelman
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,926,478.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,926,478.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,926,478.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.3 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    03940C100


    1Names of Reporting Persons

    Perceptive Life Sciences Master Fund, Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,926,478.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,926,478.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,926,478.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.3 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Arcellx, Inc.
    (b)Address of issuer's principal executive offices:

    800 Bridge Parkway, Redwood City, CA 94065
    Item 2. 
    (a)Name of person filing:

    The names of the persons filing this report (collectively, the "Reporting Persons") with respect to shares of Common Stock, par value $0.001 per share (the "Common Stock") of Arcellx, Inc. (the "Issuer") are: (i) Perceptive Advisors LLC ("Perceptive Advisors") (ii) Joseph Edelman ("Mr. Edelman") (iii) Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund")
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of each of the Reporting Persons is: 51 Astor Place, 10th Floor, New York, NY 10003
    (c)Citizenship:

    Perceptive Advisors is a Delaware limited liability company. Mr. Edelman is a United States citizen. The Master Fund is a Cayman Islands corporation.
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share
    (e)CUSIP No.:

    03940C100
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 of the cover pages to this Schedule 13G. The ownership percentages reported are based on 55,072,693 shares of Common Stock outstanding as of April 4, 2025, as reported in the Issuer's Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 17, 2025. The Master Fund directly holds 2,926,478 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund. Mr. Edelman is the managing member of Perceptive Advisors.
    (b)Percent of class:

    Perceptive Advisors: 5.3% Mr. Edelman: 5.3% Master Fund: 5.3%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0

     (ii) Shared power to vote or to direct the vote:

    Perceptive Advisors: 2,926,478 Mr. Edelman: 2,926,478 Master Fund: 2,926,478

     (iii) Sole power to dispose or to direct the disposition of:

    Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0

     (iv) Shared power to dispose or to direct the disposition of:

    Perceptive Advisors: 2,926,478 Mr. Edelman: 2,926,478 Master Fund: 2,926,478

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Perceptive Advisors LLC
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman, Managing Member
    Date:05/15/2025
     
    Joseph Edelman
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman
    Date:05/15/2025
     
    Perceptive Life Sciences Master Fund, Ltd.
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman, Managing Member
    Date:05/15/2025
    Get the next $ACLX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACLX

    DatePrice TargetRatingAnalyst
    10/8/2024$109.00Buy
    Redburn Atlantic
    9/3/2024Overweight
    Cantor Fitzgerald
    5/31/2024$70.00Overweight
    Piper Sandler
    3/7/2024$81.00Overweight
    Morgan Stanley
    1/4/2024$65.00 → $71.00Buy
    Needham
    12/19/2023$66.00Sector Outperform
    Scotiabank
    10/30/2023Outperform
    TD Cowen
    10/17/2023$52.00Buy
    UBS
    More analyst ratings

    $ACLX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025

      Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced two upcoming investor events: TD Cowen's 6th Annual Oncology Innovation Summit Tuesday, May 27, 2025 at 9:00 a.m. PT (Virtual) Management and Physician Presentation and Discussion of iMMagine-1 Pivotal Study Results During EHA2025 Friday, June 13, 2025 at 8:30 p.m. CEST (Virtual and In-Person, Milan, Italy) A live webcast of these discussions will be accessible from Arcellx's website at www.arcellx.com in the Investors section. A replay of the webcasts will be archived and available for 3

      5/21/25 4:00:00 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma

      -- Results from all 117 patients dosed in the pivotal Phase 2 iMMagine-1 study of anito-cel demonstrated 97% ORR and 68% CR/sCR at a median follow-up of 12.6 months -- -- No delayed neurotoxicities including no Parkinsonism, no cranial nerve palsies, and no Guillain-Barré syndrome, and no immune-mediated enterocolitis have been observed to date with anito-cel -- -- iMMagine-1 data to be presented during an oral presentation at EHA2025 on Saturday, June 14, 2025 -- -- Company to host a live webcast event with an expert panel of clinicians during EHA2025 -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies f

      5/14/25 9:30:00 AM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Arcellx Provides First Quarter 2025 Financial Results and Business Highlights

      -- iMMagine-1 data accepted for Oral Presentation at EHA -- -- iMMagine-3 study updated to include MRD negativity as a dual primary endpoint -- -- Added two new Board members with commercial and operational expertise -- -- Ended the quarter with $565M in cash, which is expected to fund operations into 2028 -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the first quarter ended March 31, 2025. "Delivering therapies that can positively impact patients' lives is our mission," said Rami Elg

      5/8/25 4:00:00 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ACLX
    SEC Filings

    See more
    • SEC Form 8-K filed by Arcellx Inc.

      8-K - Arcellx, Inc. (0001786205) (Filer)

      5/28/25 4:34:31 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Arcellx Inc.

      SCHEDULE 13G/A - Arcellx, Inc. (0001786205) (Subject)

      5/15/25 4:30:15 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by Arcellx Inc.

      8-K - Arcellx, Inc. (0001786205) (Filer)

      5/14/25 10:08:40 AM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ACLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Arcellx Inc.

      SC 13G - Arcellx, Inc. (0001786205) (Subject)

      11/22/24 4:12:28 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Arcellx Inc.

      SC 13G/A - Arcellx, Inc. (0001786205) (Subject)

      11/14/24 4:35:36 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Arcellx Inc.

      SC 13G/A - Arcellx, Inc. (0001786205) (Subject)

      11/14/24 4:31:50 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ACLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Behbahani Ali

      4 - Arcellx, Inc. (0001786205) (Issuer)

      5/30/25 4:33:05 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Galligan Andrew H

      4 - Arcellx, Inc. (0001786205) (Issuer)

      5/30/25 4:24:21 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Patel Kavita

      4 - Arcellx, Inc. (0001786205) (Issuer)

      5/30/25 4:20:49 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ACLX
    Financials

    Live finance-specific insights

    See more
    • Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma

      -- Collaboration leverages expertise across both companies, including Kite's global cell therapy leadership and industry leading reliable manufacturing -- -- Arcellx to receive $225M upfront payment; $100M equity investment; and up to $3.9B in total contingent consideration -- -- Companies to co-commercialize and split profits in the U.S.; Arcellx to receive low to mid-teen royalties outside the U.S. --   -- Arcellx to continue independently progressing its development pipeline and researching new product candidates beyond myeloma --  -- Arcellx to host a conference call and webcast today at 5:45 a.m. PT -- REDWOOD CITY, Calif., and SANTA MONICA, Calif., Dec. 9, 2022 /PRNewswire/ -- Arcellx

      12/9/22 8:15:00 AM ET
      $ACLX
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ACLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $ACLX
    Leadership Updates

    Live Leadership Updates

    See more
    • Redburn Atlantic initiated coverage on Arcellx with a new price target

      Redburn Atlantic initiated coverage of Arcellx with a rating of Buy and set a new price target of $109.00

      10/8/24 7:12:00 AM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald initiated coverage on Arcellx

      Cantor Fitzgerald initiated coverage of Arcellx with a rating of Overweight

      9/3/24 7:38:42 AM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Piper Sandler initiated coverage on Arcellx with a new price target

      Piper Sandler initiated coverage of Arcellx with a rating of Overweight and set a new price target of $70.00

      5/31/24 7:34:12 AM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors

      -- Mr. Galligan and Ms. Myers bring decades of experience to the company board -- -- Derek Yoon steps down from the Board of Directors -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointments of Andrew Galligan and Kristin Myers to its Board of Directors. Mr. Galligan is a proven financial executive who brings over three decades of strategic leadership experience to the Arcellx Board. Ms. Myers, a highly experienced healthcare industry executive, adds diverse expertise in operational execution, sales and marketing, and market

      3/20/25 4:00:00 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Arcellx Announces Appointment of Maryam Abdul-Kareem as General Counsel

      REDWOOD CITY, Calif., June 21, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointment of Maryam Abdul-Kareem, J.D., as General Counsel. Ms. Abdul-Kareem brings extensive legal and business expertise in the biopharmaceutical industry, including serving in senior positions at Kinnate Biopharma and AstraZeneca. At Arcellx, she will oversee a broad spectrum of legal, contracts, and compliance matters. 

      6/21/22 4:05:00 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Arcellx Appoints Michelle Gilson as Chief Financial Officer

      FOSTER CITY, Calif., May 23, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointment of Michelle Gilson as Chief Financial Officer. Ms. Gilson joins Arcellx from Canaccord Genuity, where most recently she served as Managing Director and Senior Equity Research Analyst covering biotechnology companies. Ms. Gilson will oversee the company's finance function and will play a key role in overall corporate strategy.

      5/23/22 4:05:00 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care